Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden

Blood

Volumn 123, Issue 3, 2014, Pages 338-345

  Turesson, Ingemar ^a   Kovalchik, Stephanie A ^b   Pfeiffer, Ruth M ^b   Kristinsson, Sigurdur Y ^c   Goldin, Lynn R ^b   Drayson, Mark T ^d   Landgren, Ola ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b NATIONAL CANCER INSTITUTE   (United States)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^d UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN CLASS; M PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; AMYLOIDOSIS; ARTICLE; BONE MARROW EXAMINATION; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FREE LIGHT CHAIN RATIO; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; LABORATORY TEST; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; MYELOMA PROTEINS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SWEDEN;

EID: 84893033900     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-505487     Document Type: Article

References (27)

1. Waldenström J. Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect. 1960-1961; 56: 211-231.
2. Kyle RA. Monoclonal gammopathy of undetermined signifi (Pubitemid 8328130)
3. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol. 2003; 121(5): 749-757.
4. Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980; 302(24): 1347-1349. (Pubitemid 10117727)
5. Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc. 2010; 85(10): 945-948.
6. Dispenzieri A, Katzmann JA, Kyle R.A., et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: A retrospective population-based cohort study. Lancet. 2010; 375(9727): 1721-1728.
7. Kyle RA, Therneau TM, Rajkumar S.V., et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006; 354(13): 1362-1369.
8. Kyle RA, Durie BG, Rajkumar S.V., et al.; International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010; 24(6): 1121-1127.
9. Landgren O, Kyle RA, Pfeiffer R.M., et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study. Blood. 2009; 113(22): 5412-5417.
10. Weiss BM, Abadie J, Verma P., Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009; 113(22): 5418-5422.
11. Kyle RA, Therneau TM, Rajkumar S.V., Offord JR, Larson DR, Plevak MF, Melton LJ III. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002; 346(8): 564-569. (Pubitemid 34438817)
12. Rajkumar SV, Kyle RA, Therneau T.M., et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005; 106(3): 812-817. (Pubitemid 41076419)
13. Pérez-Persona E., Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007; 110(7): 2586-2592. (Pubitemid 47523182)
14. Eisele L, Dürig J, Hüttmann A, et al.; Heinz Nixdorf Recall Study Investigative Group. Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. Ann Hematol. 2012; 91(2): 243-248.
15. Socialstyrelsen. Cancer Incidence in Sweden 2006. Stockholm, Sweden: Centre for Epidemiology; 2007.
16. Turesson I, Linet MS, Björkholm M, Kristinsson S.Y., Goldin LR, Caporaso NE, Landgren O. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer. 2007; 121(10): 2260-2266. (Pubitemid 47585607)
17. Anonymous. Patientregistret 1987-1996: Kvalitet och Innehåll (Swedish). Stockholm, Sweden: EpC, National Board of Health and Wellfare; 1998.
18. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94(446): 496-509.
19. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994; 81(3): 515-526.
20. Molinaro AM, Simon R, Pfeiffer RM. Prediction error estimation: A comparison of resampling methods. Bioinformatics. 2005; 21(15): 3301-3307. (Pubitemid 41418445)
21. Kyle RA, Therneau TM, Rajkumar S.V., et al. Longterm follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003; 102(10): 3759-3764. (Pubitemid 37409398)
22. Schuster SR, Rajkumar SV, Dispenzieri A, et al. IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. Am J Hematol. 2010; 85(11): 853-855.
23. Blade J, Lopez-Guillermo A, Rozman C., et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol. 1992; 81(3): 391-394.
24. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy. 1969; 13: 1-110.
25. Cesana C, Klersy C, Barbarano L., et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol. 2002; 20(6): 1625-1634. (Pubitemid 34260544)
26. van de Poel MH, Coebergh JW, Hillen HF. Malignant transformation of monoclonal gammopathy of undetermined significance among out-patients of a community hospital in southeastern Netherlands. Br J Haematol. 1995; 91(1): 121-125.
27. Gregersen H, Mellemkjaer L, Ibsen J.S., Dahlerup JF, Thomassen L, Sørensen HT. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica. 2001; 86(11): 1172-1179. (Pubitemid 33063863)